AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT01489722
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
The Use of International GerdQ Questionnaire
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT01489735
- Locations
- 🇷🇺
Research site, Moscow, Russian Federation
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
Phase 1
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01486433
Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values
Completed
- Conditions
- Hypercholesterolaemia
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT01483950
- Locations
- 🇧🇦
Research Site, Zvornik, Bosnia and Herzegovina
🇧🇦Reserach Site, Gradiška, Bosnia and Herzegovina
Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 147
- Registration Number
- NCT01482884
- Locations
- 🇬🇧
Research Site, Shrewsbury, United Kingdom
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
Phase 2
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: AZD6765 ivDrug: Placebo
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 542
- Registration Number
- NCT01482221
- Locations
- 🇿🇦
Research Site, Tygervalley, South Africa
AZD5069 Neutrophil Function Study
Phase 1
Completed
- Conditions
- Chemokine Receptor 2 (CXCR2) Antagonist
- Interventions
- Drug: 100 mg (50 mg x 2) AZD5069Drug: 100 mg Placebo
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01480739
Pattern of Statins Use in Catalonia
Completed
- Conditions
- Hypercholesteremia
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180723
- Registration Number
- NCT01477944
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Phase 2
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 81
- Registration Number
- NCT01473758
- Locations
- 🇬🇧
Academic Unit of Respiratory Medicine, Royal Free Hospital, Jadwiga A. Wedzicha, London, United Kingdom
Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT01471171
- Locations
- 🇩🇪
Almirall Investigational Site #3, Hannover, Germany
🇩🇪Almirall Investigational Site #8, Hamburg, Germany
🇩🇪Almirall Investigational Site #6, Berlin, Germany